Cancer Statistics, 2005

Abstract

Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute and mortality data from the National Center for Health Statistics. among women. The mortality rate has also continued to decrease from the three most common cancer sites in men (lung and bronchus, colon and rectum, and prostate) and from breast and colorectal cancers in women. Lung cancer mortality among women has leveled off after increasing for many decades. In analyses by race and ethnicity, African American men and women have 40% and 20% higher death rates from all cancers combined than White men and women, respectively. Cancer incidence and death rates are lower in other racial and ethnic groups than in Whites and African Americans for all sites combined and for the four major cancer sites. However, these groups generally have higher rates for stomach, liver, and cervical cancers than Whites. Furthermore, minority populations are more likely to be diagnosed with advanced stage disease than are Whites. Progress in reducing the burden of suffering and death from cancer can be accelerated by applying existing cancer control knowledge across all segments of the population. (CA Cancer J Clin 2005;55:10 -30.)

siRNA-based approaches in cancer therapy

“…1 These morbid statistics demonstrate the necessity of newer therapeutic modalities for achieving successful cancer treatment and cure. Downregulation of genes that contribute to cancer progression has been the goal of targeted genomics-based strategies, with the expectation that such an approach may lead to selective and specific inhibition of tumor growth with minimal untoward side effects on normal cells.…”

Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer

“…In all, 10-20% of all recurrences are locoregional, whereas 60-70% are distant metastases. [1][2][3] Despite multimodal treatment, including chemotherapy and hormonal therapy, the prognosis for patients with recurrent or metastatic breast cancer remains poor. 4 Therefore, more specific, safe and effective treatment modalities are required.…”

Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene

“…Renal cancer constitutes approximately 3% of all human cancers and accounts for 2.6% of all cancer deaths (Cohen and McGovern, 2005;Jemal et al, 2005).…”